Josephine van Dongen

Chapter 7 174 References 1. Narváez J, Osorio MB, Castañeda-Orjuela C, et al. Is Colombia reaching the goals on infant immunization coverage? A quantitative survey from 80 municipalities. Vaccine . Published online 2017. doi:10.1016/j.vaccine.2017.01.073 2. Levine et al., Osinusi K. The future of immunisation policy, implementation, and fi nancing. Lancet. 2011;(378):439-448. doi:10.1016/S0140 3. Sjö Gren E,Ask LS, Rtqvist K,Asp M. Parental conceptions of the rotavirus vaccine during implementation in Stockholm: A phenomenographic study. J Child Heal Care . 2017;21(4):476- 487. doi:10.1177/1367493517734390 4. Veldwijk J, Lambooij MS, Bruijning-Verhagen PCJ, Smit HA, Wit GA de. Parental preferences for rotavirus vaccination in young children: A discrete choice experiment. Vaccine . 2014;32(47):6277-6283. doi:10.1016/J.VACCINE.2014.09.004 5. Glanz JM, Newcomer SR, Narwaney KJ, et al. A population-based cohor t study of undervaccination in 8 managed care organizations across the United States. JAMA Pediatr. 2013;167(3):274-281. doi:10.1001/jamapediatrics.2013.502 6. Çataklı T, Duyan-Çamurdan A, Aksakal-Baran FN, Güven AE, Beyazova U. Attitudes of physicians concerning vaccines not included in the national immunization schedule. Turk J Pediatr . Published online 2018. doi:10.24953/turkjped.2018.03.009 7. Mita V, Arigliani M, Zaratti L, Arigliani R, Franco E. Italian Physicians’ Opinions on Rotavirus Vaccine Implementation. Pathogens . 2017;6(56). doi:10.3390/pathogens6040056 8. Dubé E, Gilca V, Sauvageau C, et al. Clinicians’ opinions on new vaccination programs implementation. Vaccine. 2012;30(31):4632-4637. doi:10.1016/j.vaccine.2012.04.100 9. Global Introduction status - Rotavirus. Accessed June 21, 2019. http://rotacouncil.org/ vaccine-introduction/global-introduction-status/ 10. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and Efficacy of an AttenuatedVaccine against Severe Rotavirus Gastroenteritis. N Engl J Med . 2006;354(1):11-22. doi:10.1056/NEJMoa052434 11. Itzler R, Koch G, Matson DO, et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassor tant pentavalent rotavirus vaccine (RV5). BMC Pediatr . 2010;10. http://www.biomedcentral . com/1471-2431/10/42 12. Vesikari T, Matson DO, Dennehy P, et al. Safety and Efficacy of a Pentavalent Human– Bovine (WC3) Reassor tant Rotavirus Vaccine. N Engl J Med . 2006;354(1):23-33. doi:10.1056/ NEJMoa052664 13. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine . 2004;22(21):2836-2842. doi:10.1016/j.vaccine.2004.01.044 14. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq??, a pentavalent rotavirus vaccine: Efficacy and safety among infants in Europe. Vaccine . Published online 2009. doi:10.1016/j. vaccine.2009.10.041 15. ToendersWGM. CFH-Rappor t Beoordeling Rotavirus RIX4414 (Rotarix).Vol 3.; 2007. 16. Bruijning-Verhagen P, Mangen M-JJ, Felderhof M, et al.Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med . 2013;11(112). doi:10.1186/1741-7015-11-112 17. Bruijning-Verhagen PCJ. RIVAR study protocol. Published 2014. Accessed November 17, 2020. https://www.trialregister.nl/trial/5213 18. BraunV,ClarkeV.Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-